3 active not recruiting, 2 recruiting, 1 withdrawn. 3 Phase 1, 2 Early Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Recruiting 1 |
| Early Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Advanced Primary Peritoneal Carcinoma: new trials by email Literature Review of Advanced Primary Peritoneal Carcinoma trials Research Report on Advanced Primary Peritoneal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 | |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2016-02-04 | 2026-10-06 |
Fallopian Tube Neoplasms (5) · Ovarian Neoplasms (4) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Sarcoma, Synovial (1) · Triple Negative Breast Neoplasms (1)
Adnexal Diseases (5) · Fallopian Tube Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Neoplasms (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Gonadal Disorders (4) · Ovarian Diseases (4)
Biopsy (2) · Leukapheresis (2) · Specimen Handling (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · BAY 1895344 (1) · Cyclophosphamide (1) · Decitabine (1) · Diphtheria Toxoid (1) · Diphtheria-Tetanus Vaccine (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Gemcitabine (1) · Injections (1) · Magnetic Resonance Spectroscopy (1) · Taxes (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1)
United States (5)
Apostolia M Tsimberidou (1) · Evthokia Hobbs, M.D. (1) · James M Cleary (1) · Matthew S. Block, MD, PhD (1) · Philip McCarthy, MD (1) · Shannon N Westin (1)
P30CA016056 (1), R01CA164333 (1), UM1CA186709 (1)